

REMARKS

By this amendment, the symbols used in SEQ ID NOs: 6-8 in the specification are made to conform to those used in the sequence listing, submitted herewith. In this amendment, the symbol "B" is replaced by the symbol "N" for the designation of 5-bromocytosine, in accord with the base codes outlined in 37 C.F.R. §1.822. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with marking to show changes made."

Examination on the merits is respectfully requested.

In the event that there are any questions concerning this amendment or the application in general, the Examiner is respectfully urged to telephone the undersigned representative so that prosecution may be expedited.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 377882001420.

BEST AVAILABLE COPY

However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: November 26, 2001

By:

Karen R. Zachow
Karen R. Zachow
Registration No. 46,332

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5895
Facsimile: (650) 494-0792

BEST AVAILABLE COPY

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification

Please replace the paragraph at page 22, beginning at line 19, with the following paragraph.

In some embodiments, the immunomodulatory polynucleotide comprises the sequence 5'-TGACTGTGAACGTTTCGAGATGA-3' (SEQ ID NO:1). In other embodiments, the ISS comprises any of the sequences:

5'-TGACCGTGAACGTTTCGAGATGA-3' (SEQ ID NO:2);

5'-TCATCTCGAACGTTCCACAGTCA-3' (SEQ ID NO:3);

5'-TGACTGTGAACGTTCCAGATGA-3' (SEQ ID NO:4)

5'-TCCATAACGTTTCGCCTAACGTTTCGTC-3' (SEQ ID NO:5)

[5'-TGACTGTGAABGTTCCAGATGA-3'] 5'-TGACTGTGAANGTTCCAGATGA-3'

(SEQ ID NO:6), where [B]N is 5-bromocytosine;

[5'-TGACTGTGAABGTTTCGAGATGA-3'] 5'-TGACTGTGAANGTTTCGAGATGA-3'

(SEQ ID NO:7), where [B] N is 5-bromocytosine;

[5'-TGACTGTGAABGTTBGAGATGA-3'] 5'-TGACTGTGAANGTTNGAGATGA-3'

(SEQ ID NO:8), where [B] N is 5-bromocytosine and

5'-TCGAGCGTTCT-3' (SEQ ID NO:21);

5'-ATCGACTCTCGAGCGTTCTC-3' (SEQ ID NO:22) and

5'-TCGTCGTTTTGTCGTTTTGTCGTT-3' (SEQ ID NO:23).

BEST AVAILABLE COPY